Our mission is to develop gene therapies that modulate the immune system to address unmet treatment needs, especially serious debilitating illnesses.
Gene therapy for treating autoimmune diseases
Our lead agent is Wyvern CP, a gene therapy that treats autoimmune diseases without using immunosuppressive agents or causing serious side effects, such as cytokinemia.
- First clinical study, examining the up-regulation of immune modulators in human lung patients, commenced in Q4 2017.
- First randomized study currently in the planning stages.
Gene therapy for treating infectious diseases
Our follow-on agent is Wyvern DR, a gene therapy that treats infectious diseases, including antibiotic - and antiviral-resistant infections.
- First clinical trial, examining reduction of viral load in patients with respiratory syncytial virus (RSV), in the planning stages.
Founded in 2017, Wyvern Pharmaceuticals Inc. is a privately held biopharmaceutical company headquartered in Calgary, Canada.
Our executive team brings together decades of experience in drug development and taking new therapies to market. Together, we aim to deliver meaningful quality of life and lifespan extension benefits to patient populations with serious unmet treatment needs.
We are beginning this journey with proprietary technologies that use gene therapy to safely and effectively treat serious debilitating illnesses, including autoimmune disorders and infectious diseases.